{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "ONCTERNAL THERAP.  DL-,01", "longName": "Oncternal Therapeutics, Inc.", "messageBoardId": "finmb_344890993", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 0.256, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.054000005, "fiftyTwoWeekLowChangePercent": 0.26732674, "fiftyTwoWeekRange": "0.202 - 1.55", "fiftyTwoWeekHighChange": -1.2939999, "fiftyTwoWeekHighChangePercent": -0.8348387, "fiftyTwoWeekLow": 0.202, "fiftyTwoWeekHigh": 1.55, "earningsTimestamp": 1683234000, "earningsTimestampStart": 1691438400, "earningsTimestampEnd": 1691784000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.68, "epsForward": -0.84, "epsCurrentYear": -0.61, "priceEpsCurrentYear": -0.41967213, "sharesOutstanding": 58711500, "bookValue": 1.061, "fiftyDayAverage": 0.490448, "fiftyDayAverageChange": -0.23444799, "fiftyDayAverageChangePercent": -0.47802824, "twoHundredDayAverage": 0.863969, "twoHundredDayAverageChange": -0.60796905, "twoHundredDayAverageChangePercent": -0.7036931, "marketCap": 19680104, "forwardPE": -0.30476192, "priceToBook": 0.24128182, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": 15.31532, "regularMarketPrice": 0.256, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1086156000000, "priceHint": 4, "regularMarketChange": 0.03400001, "regularMarketTime": 1683880220, "regularMarketDayHigh": 0.256, "regularMarketDayRange": "0.256 - 0.256", "regularMarketDayLow": 0.256, "regularMarketVolume": 1500, "regularMarketPreviousClose": 0.222, "bid": 0.216, "ask": 0.314, "symbol": "GTU2.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "12230 El Camino Real", "address2": "Suite 300", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 434 1113", "fax": "858 408 3010", "website": "https://www.oncternal.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Dr. James B. Breitmeyer M.D., Ph.D.", "age": 68, "title": "Pres, CEO & Director", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": {"raw": 814673, "fmt": "814.67k", "longFmt": "814,673"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 57617, "fmt": "57.62k", "longFmt": "57,617"}}, {"maxAge": 1, "name": "Dr. Gunnar F. Kaufmann Ph.D.", "age": 46, "title": "Chief Scientific Officer", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 548736, "fmt": "548.74k", "longFmt": "548,736"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Salim  Yazji M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 549206, "fmt": "549.21k", "longFmt": "549,206"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Richard G. Vincent CPA", "age": 58, "title": "CFO & Treasurer", "yearBorn": 1964, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Rajesh  Krishnan Ph.D.", "age": 49, "title": "Chief Technology Officer", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Chase C. Leavitt", "age": 40, "title": "Gen. Counsel & Sec.", "yearBorn": 1982, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Pablo  Urbaneja", "title": "Sr. VP of Corp. Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}